中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 昆明植物研究所
  3. 中国科学院昆明植物研究所
  4. 植物化学与西部植物资源持续利用国家重点实验室
Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines

文献类型：期刊论文

作者Wang, Hui-Li1; Liu, Yan-Chun2; Long, Ming-Peng1; Zheng, Chuan1; Yang, Jia-Hui1
刊名ONCOLOGY LETTERS
出版日期2019-09-01
卷号18期号:3页码:2977-2984
关键词receptor tyrosine kinase-like orphan receptor 1 lung adenocarcinoma erlotinib resistance AKT mammalian target of rapamycin small interfering RNA
ISSN号1792-1074
DOI10.3892/ol.2019.10643
通讯作者Zheng, Chuan(alonzc@163.com) ; Yang, Jia-Hui(yangjiahui@cdutcm.edu.cn)
英文摘要Treatment strategies involving tyrosine kinase inhibitors (TKIs) for patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations have advanced significantly; however, challenges still remain regarding the development of resistance. It has been reported that receptor tyrosine kinase-like orphan receptor 1 (ROR1) acts as a hepatocyte growth factor receptor (MET) and c-Src substrate, and that the extracellular domain of ROR1 is associated with EGFR to sustain EGFR-ERBB3-PI3K signaling. Our previous study reported that blocking ROR1 significantly decreased the activity of key signal molecules in the AKT/mammalian target of rapamycin (mTOR) signaling pathway, which was associated with a significant increase of apoptosis and significant decrease of proliferation of lung adenocarcinoma cells. The present study hypothesized that inhibiting ROR1 could potentially prevent erlotinib resistance in NSCLC cell lines. Investigations were performed with two erlotinib-resistant cell lines XLA-07 and NCI-H1975, and an erlotinib-acquired-resistant cell line PC-9erlo, which was developed from its parental cell line PC-9. It was identified that the inhibition of ROR1 via small interfering RNA treatment significantly improved the anti-proliferation and apoptosis-inducing roles of erlotinib in TKI-resistant tumor cells. This was in accordance with the activity of key molecules of the AKT/mTOR signaling pathway, including glycogen synthase kinase-3 alpha/beta (GSK-3 alpha/beta), phosphatase and tensin homolog (PTEN), AKT, mTOR and ribosomal protein S6 kinase beta-1 (p70S6K). The current data suggest that targeting ROR1 is a potential novel treatment strategy for patients with ROR1-positive NSCLC, particularly those with acquired resistance to EGFR-TKI.
WOS研究方向Oncology
语种英语
WOS记录号WOS:000487675500101
源URL[http://ir.kib.ac.cn/handle/151853/69449]  
专题昆明植物研究所_植物化学与西部植物资源持续利用国家重点实验室
通讯作者Zheng, Chuan; Yang, Jia-Hui
作者单位1.Chengdu Univ Tradit Chinese Med, Sch Basic Med, 1166 Liutai Ave, Chengdu 611137, Sichuan, Peoples R China
2.Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming 650201, Yunnan, Peoples R China
推荐引用方式
GB/T 7714		 Wang, Hui-Li,Liu, Yan-Chun,Long, Ming-Peng,et al. Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines[J]. ONCOLOGY LETTERS,2019,18(3):2977-2984.
APA Wang, Hui-Li,Liu, Yan-Chun,Long, Ming-Peng,Zheng, Chuan,&Yang, Jia-Hui.(2019).Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines.ONCOLOGY LETTERS,18(3),2977-2984.
MLA Wang, Hui-Li,et al."Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines".ONCOLOGY LETTERS 18.3(2019):2977-2984.

入库方式： OAI收割

来源：昆明植物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。